UNSPSC 51422309: Difluprednate

This classification denotes a therapeutic glucocorticoid with the molecular formula C27H34F2O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S8A06QG2QE, chemically known as 21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione (6alpha,11beta)- but generally known as difluprednate, which bears US NIH Compound Identifier 32037. European Medicines Agency schedules Difluprednate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07131MIG.

UNSPSC 51422309 Difluprednate is a Commodity code that appears in state and local procurement records with minimal recent activity directly aligned to its scope. The single representative recent opportunity tagged under this code—Seminole County, Florida's IFB60459723LAS for Naloxone and Safe Drug Deactivation Systems—does not procure difluprednate, a corticosteroid ophthalmic suspension used in eye inflammation treatment. The Seminole County solicitation seeks 1,900 units of naloxone (an opioid antagonist) and 800 safe drug deactivation systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building and a two-year initial term plus one-year renewal option. A second record, the Texas Health and Human Services Commission's RFI HHS0017013 on Direct-to-Manufacturer Prescriptions, similarly does not align to difluprednate procurement but rather explores statewide pharmacy benefit strategy and vendor capacity for direct contracting with manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The mismatch between the code's nominal scope and these recent opportunities suggests the code carries minimal relevant state and local contracting activity at present.

The geographic spread among recent records is limited to Florida and Texas, with the Seminole County IFB representing the sole concrete procurement opportunity and the Texas HHS RFI serving as exploratory market research rather than a formal solicitation. No issuers beyond these two jurisdictions appear in the recent record, and no vendor names, awarded contractors, set-aside designations, or explicit budget figures are disclosed for difluprednate-specific work. Business development professionals evaluating this code should treat it as inactive in state and local procurement and monitor for future opportunities as state health agencies or local public health departments address ophthalmic pharmaceutical needs through formal solicitation vehicles.